Results 1 to 10 of about 6,309 (194)

Real‐world effectiveness of targeted therapies in ATTR cardiomyopathy: A meta‐analysis integrating population‐based data [PDF]

ESC Heart Failure
Aims The aim of this meta‐analysis was to evaluate the effects of targeted treatments for transthyretin amyloid cardiomyopathy (ATTR‐CM) on clinical outcomes by integrating clinical trial and real‐world data.
Alexios S. Antonopoulos, Theodoros Tsampras, Dimitrios Terentes‐Printzios, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +5 more
doaj   +3 more sources

Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score–Weighted Cohort Study [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin cardiac amyloidosis results from the deposition of misfolded amyloid fibrils in cardiac tissue, leading to progressive heart failure.
Louise Zmuda, Amira Zaroui, Mounira Kharoubi, Emmanuelle Boutin, Frédéric Roca, Silvia Oghina, Emmanuel Teiger, Marie Laurent, Florence Canoui‐Poitrine, Thibaud Damy, Amaury Broussier   +10 more
doaj   +2 more sources

Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy [PDF]

Cardiology and Therapy
Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Tafamidis demonstrated efficacy in ATTR-CM clinical trials; however, real-world disease outcomes are not thoroughly characterized.
Daniel P. Judge, Margarita Udall, Andrew M. Rosen, Neil Lamarre, Elizabeth Nagelhout, Hanh Dung Dao, Mathew S. Maurer   +6 more
doaj   +2 more sources

Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOS [PDF]

Cardiology and Therapy
Introduction Tafamidis is approved to treat transthyretin amyloid cardiomyopathy (ATTR-CM). Many patients with ATTR-CM present with a mixed phenotype of both cardiac and neurologic symptoms, but real-world effectiveness studies of tafamidis in this ...
Jonas Wixner, Angela Dispenzieri, Leslie Amass, Martin Carlsson, Steve Riley, Evan Powers, Jeffery W. Kelly, the THAOS investigators   +7 more
doaj   +2 more sources

Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Diagnostic rates of transthyretin cardiac amyloidosis have increased due to growing awareness, noninvasive diagnoses, and treatments that improve morbidity and mortality.
Brett W. Sperry, Ahmad Masri, Prem Soman, Ain U. Ejaz, Priyanka Bhattacharya, Brent Medoff, Pranav Chandrashekar, Lauren Ives, Alfonsina Mirabal Santos, Sergio L. Teruya, Yanjun Wu, Yuanzi Zhao, Xiaofeng Wang, Mathew S. Maurer, Mazen Hanna   +14 more
doaj   +2 more sources

Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis [PDF]

JACC: Advances
Background: Atrial fibrillation/flutter (AF) is common in transthyretin cardiac amyloidosis (ATTR-CA). The CHARGE-AF score has not been validated in ATTR-CA.
Nicholas Chan, MD, MS, Yevgeniy Brailovsky, DO, MSc, Sergio Teruya, MD, MS, Alfonsina Mirabal, MD, Ariel Y. Weinsaft, Jeffeny De Los Santos, MD, MHA, Samantha Guadalupe, MHA, Massiel Jimenez, MD, Stephen Helmke, RDCS, MPH, Margaret Cuomo, MSN, FNP-C, Dia Smiley, DO, Angelo Biviano, MD, Jose Dizon, MD, Elaine Wan, MD, Hirad Yarmohammadi, MD, Mathew S. Maurer, MD   +15 more
doaj   +2 more sources

Effects of Tafamidis Meglumine on Transient Focal Neurological Episodes and Meningeal Contrast Enhancement in Hereditary Transthyretin‐Related Meningeal Amyloidosis: Report of Two Patients Carrying the c.265T>C (p.Y89H) Variant [PDF]

Brain and Behavior
Background Y69H (p.Y89H) variant hereditary transthyretin (ATTRv) amyloidosis causes meningeal amyloidosis, with mutant TTR deposits localized to the leptomeninges and vitreous body.
Natsumi Saito, Yasuko Kuroha, Ayaka Ishiyama, Takahiro Wakasugi, Takayoshi Tokutake, Arika Hasegawa, Tetsuya Takahashi   +6 more
doaj   +2 more sources

Concurrent Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patient Treated With Daratumumab and Tafamidis: A Case Report [PDF]

eJHaem
Immunoglobulin light chain (AL) and wild‐type transthyretin (ATTRwt) amyloidosis, while sharing similar clinical presentations, require distinct treatments.
Taiki Nishihara, Yawara Kawano, Masayoshi Tasaki, Ayuko Naito, Hiromichi Yuki, Yasuhiro Nagayoshi, Seiji Takashio, Nao Nishimura, Mitsuharu Ueda, Kenichi Tsujita, Jun‐Ichirou Yasunaga   +10 more
doaj   +2 more sources

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysisResearch in context

EClinicalMedicine, 2023
Summary: Background: Previous studies have reported that tafamidis treatment was associated with better outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with those without tafamidis treatment.
Jie Wang, Hongyu Chen, Zihuan Tang, Jinquan Zhang, Yuanwei Xu, Ke Wan, Kifah Hussain, Georgios V. Gkoutos, Yuchi Han, Yucheng Chen   +9 more
doaj   +1 more source

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy

ESC Heart Failure, 2023
Aims Tafamidis improves prognosis in patients with transthyretin amyloid cardiomyopathy (ATTR‐CM). However, real‐world data on the therapeutic effect of tafamidis are lacking.
Seiji Takashio, Mami Morioka, Masanobu Ishii, Kei Morikawa, Kyoko Hirakawa, Shinsuke Hanatani, Fumi Oike, Hiroki Usuku, Masafumi Kidoh, Seitaro Oda, Eiichiro Yamamoto, Kenichi Matsushita, Mitsuharu Ueda, Kenichi Tsujita   +13 more
doaj   +1 more source